Healthcare Industry News: Helixis
News Release - October 5, 2007
Helixis, Inc. Announces Advanced Technology Ventures' Role in Series A Financing
CARLSBAD, Calif.--(HSMN NewsFeed)--Helixis, Inc., an early-stage company focused on the development of low-cost, fast and accurate molecular diagnostic products and research instruments, today announced the participation of Advanced Technology Ventures (ATV) in the Company's $10 million Series A round completed in late August, joining Domain Associates and Okapi Venture Capital."We are very pleased to be able to announce ATV's role in the financing," said Alex Dickinson, president, chief executive officer and co-founder, Helixis. "We are now in the fortunate position of welcoming them publicly to both the Series A syndicate and our Board."
In conjunction with the ATV investment, Ken Noonan, Ph.D., a Venture Partner with ATV, has joined Helixis' Board of Directors.
"Helixis has the potential to significantly increase the affordability and availability of molecular analytic technology in both the laboratory and the clinic, as well as expand its use to contiguous fields," said Tom Rodgers, Principal, Advanced Technology Ventures, who led the firm's investment in Helixis. "We look forward to working with Alex and his team to realize this potential."
About Advanced Technology Ventures
Founded in 1979, Advanced Technology Ventures (ATV) is a bi-coastal venture capital firm with more than $1.4 billion in capital under management. ATV works closely with entrepreneurial teams in several technology markets, including medical devices, biopharmaceuticals, diagnostics, clean tech, and various information technology sectors, to build emerging-growth business ventures into market leaders. With more than 27 years of experience, ATV has a proven track record of success in helping to build strong, sustainable business enterprises. For more information, please visit our Web site at www.atvcapital.com.
About Domain Associates, LLC
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.1 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain's three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. For more information, visit www.domainvc.com.
About Okapi Venture Capital, LLC
Founded in 2006, Okapi Venture Capital is a seed and early-stage venture capital fund headquartered in Laguna Beach, California. Okapi, with approximately $30 million dollars under management in its current fund, Okapi Ventures I, is focused on seed and early-stage life sciences and information technology opportunities in Southern California. For more information about Okapi, visit www.okapivc.com.
About Helixis, Inc.
Helixis, Inc. is an early-stage diagnostics company focused on the development of low-cost, fast and accurate molecular diagnostic products. Founded in 2007 by several of the world's most respected molecular biologists and engineers, the company has a mission to make advanced molecular diagnostic products more accessible for critical medical and scientific applications in both the developed and developing worlds. Helixis is headquartered in Carlsbad, CA. For more information, visit www.Helixis.com.
Source: Helixis
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
